Heart Drug Has Serious Side Effects

March 31, 2002

MEDLINEplus: Heart Drug Has Serious Side Effects

-

* Health and Healing *

Sunday, March 31, 2002 3:10 PM

Heart Drug Has Serious Side Effects

- http://www.nlm.nih.gov/medlineplus/news/fullstory_6814.html -

Heart Drug Has Serious Side Effects

Associated Press

By LINDSEY TANNER AP Medical Writer

Tuesday, March 26, 2002

CHICAGO (AP) - A drug commonly used for short-term treatment of worsening heart

failure in hospitalized patients may cause dangerously low blood pressure and

abnormal heart rhythms, researchers found.

The findings suggest that the drug, milrinone, should be reserved for patients

who do not respond to other medication, said Dr. Mihai Gheorghiade of

Northwestern University.

The study is one of the few to compare a placebo with a drug for worsening heart

failure, a condition that sends about 1 million Americans to the hospital each

year. Despite the poor results, it shows that such studies can and should be

done on similar drugs, Gheorghiade said.

``We should not take things for granted just because they have been approved, to

assume they are useful,'' said Gheorghiade, who led the study, published in

Wednesday's Journal of the American Medical Association.

An accompanying editorial says the use of other drugs commonly used in worsening

heart failure, dopamine and dobutamine, should be reconsidered given the

milrinone findings, since all three drugs work similarly to strengthen the

heartbeat. Milrinone, sold as Primacor, was approved in 1987.

Heart failure, in which the heart gradually loses its ability to pump blood

efficiently, affects nearly 5 million Americans. The condition may be chronic,

but patients can develop severe attacks of breathing difficulty that require

hospitalization.

Dr. Ann Bolger, an American Heart Association spokeswoman, said patients studied

were generally less sick than those who typically would be given milrinone. The

study shows ``there really isn't any advantage'' to giving milrinone to patients

who are not acutely ill, Bolger said.

Sanofi-Synthelabo Inc., which markets milrinone in the United States, funded the

study. The company's Web site warns that the drug may cause irregular

heartbeats, and says milrinone should be stopped if blood pressure falls too

low. It also says that the drug may not be safe or effective when given for

longer than 48 hours, and that long-term oral treatment has been linked with an

increased risk of hospitalization and death.

Another JAMA study shows favorable results for a newer drug called Natrecor,

approved last year for worsening heart failure. Known chemically as nesiritide,

the drug improved breathing and blood flow, and appeared to work more quickly

than intravenous nitroglycerin.

Dr. Michael Cuffe, a Duke University cardiologist who helped lead the milrinone

study, said the research looked at how patients fared over the longer term,

unlike the research that led to government approval of the drug.

The study involved 949 patients given either a dummy drug or a 48-hour milrinone

infusion.

Dangerously low blood pressure occurred much more frequently in milrinone

patients, 10.7 percent compared with 3.2 percent of the placebo patients; as did

irregular heartbeats, 4.6 percent versus 1.5 percent.

The average length of hospitalization did not differ significantly - six days

for milrinone and seven days for placebo. Sixty-day death rates - 10.3 percent

in milrinone patients and 8.9 percent in placebo patients - also did not differ

significantly.

On the Net:

JAMA: http://jama.ama-assn.org

Sanofi-Synthelabo: http://www.sanofi-synthelabous.com

published, broadcast, rewritten, or redistributed.

Sign In

Heart Drug Has Serious Side Effects

Recommended Posts

Guest guest

Link to comment

Share on other sites

Join the conversation

Support the Ashram

Join Groups

Top Downloads